Top of this page
Skip navigation, go straight to the content
We are now entering its next?phase which we call?
?
We will accelerate our growth potential by maximizing patients’ access to our key medicines, by further improving our ability to demonstrate differentiation and by accelerating the development timelines through new approaches.
The successful evolution of our late stage pipeline requires additional resources in the short-term therefore we will continue to invest significantly into R&D to deliver breakthrough medicines with sustainable value propositions for patients, healthcare professionals and payers and securing UCB sustainability.
Thanks to its strong financial foundations, UCB will selectively use its financial and strategic flexibility to complement its internal pipeline with external innovative assets, programs or platforms through partnerships, licenses or acquisitions.
?
?
?
*?subject to approval
In these areas, we have 5 main medicines on the market.
?
To create a pipeline that will make a real difference in people’s lives, we have to remain focused on our key assets: our expertise in small and large molecules and our expertise in the fields of neurology and auto-immune diseases.
For a company of our size, we consider it is vital to remain focused.
?
?
*?subject to approval
July 2019
CIDP: Chronic Inflammatory Demyelinating Polyneuropathy
?
Changes since February 2019: